Febrile neutropenia/antifungal drug trial design
FDA will hold a public workshop on clinical trial design for febrile neutropenia and antifungal combination therapies on Sept. 4. The meeting, co-sponsored by the National Institute of Allergy & Infectious Diseases, will take place at the Hyatt Regency in Bethesda, Md., beginning at 1 p.m. [To view a webcast or live videoconference of this meeting, contact email@example.com or call 800-332-1370 ext. 7210]...
You may also be interested in...
The Personal Care Products Council’s Francine Lamoriello, EVP of global strategies, discusses shortcomings of a proposed animal-testing exemption for imported general cosmetics under a key implementing regulation drafted for China’s new cosmetics oversight framework.
Two months after submitting CBD enforcement draft guidance for OMB review, FDA published separate draft guidance on studies for bioequivalents of an approved cannabidiol-based drug. But the draft guidance that the supplement industry awaits in pitched anticipation remains under review.
FDA schedules public meeting for 19 November to discuss sex and gender differences in the use and response to cannabidiols. The meeting will address the issue of CBD use in pregnancy, for which no human data currently is available.